CoChat

The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets

Open access
Steckelings, Ulrike Muscha, Rompe, Franziska, Kaschina, Elena, Unger, Thomas · 2009 · Fundamental & Clinical Pharmacology
Cited by 92

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The phylogenetically old renin‐angiotensin‐system (RAS) was originally described as a circulating hormonal system and a main cardiovascular regulator. However, there also exist ‘local RASs’ which are situated in cardiovascular as well as non‐cardiovascular tissues where they are involved in physiological and patho‐physiological processes such as inflammation, fibrosis, proliferation or apoptosis. Local RASs are activated in diabetes, preferentially in organs affected by hyperglycaemic injury such as the kidney or the retina. Increased renal or retinal Ang II levels may contribute to diabetic tissue injury in two ways: (i) by stimulating the angiotensin AT1‐receptor and downstream pathological chains of events and (ii) by bidirectional interaction with the ‘classical’ hyperglycaemia‐induced pathobiochemical pathways (oxidative stress, generation of advanced glycation end products, increased polyol pathway flux, activation of protein kinase C, increased hexosamine pathway flux). The involvement of the RAS in the pathomechanisms underlying diabetic end organ damage suggests pharmacological RAS inhibition as a therapeutic approach in these disorders. This assumption has been supported by numerous animal studies. Clinically, RAS inhibition is currently the first line, guideline‐approved treatment in diabetic nephropathy. The recently published DIRECT, RASS and AdRem studies provided evidence that RAS inhibition may also be beneficial in diabetic retinopathy; however, evidence for RAS‐inhibition in retinopathy is still much weaker than for nephropathy. The present article reviews the emerging knowledge about cardiovascular and non‐cardiovascular effects of the RAS with an emphasis on the mechanisms of RAS involvement and pharmacological RAS inhibition in diabetic end organ damage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1472-8206.2009.00780.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 92

Metadata

Authors
Steckelings, U. M., Rompe, F., Kaschina, E., & Unger, T.
Venue
Fundamental & Clinical Pharmacology
Publisher
Wiley
Published
2009-11-10
Volume
23
Issue
6
Pages
693-703
ISSN
  • 0767-3981 (ISSN-L)
  • 1472-8206
OpenAlex
W2092808370
Cited by
92
References
7
FWCI
7.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets. https://app.cochat.ai/papers/10.1111/j.1472-8206.2009.00780.x
The paper
Steckelings, U. M., Rompe, F., Kaschina, E., & Unger, T. (2009). The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.2009.00780.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.